Literature DB >> 792855

Steroids and the eye--indications and complications.

W J Dinning.   

Abstract

Corticosteroid therapy is of great value in many types of eye disease. The indications are briefly discussed, together with the choice of agent and mode of administration. The dangers of steroids are now widely recognized, and the complications are discussed, particularly cataract and glaucoma. Reference is also made to optic neuritis and thyroid ophthalmopathy, where the role of steroids is uncertain. Particular stress is laid on the need to keep steroid dosage as low as possible, so as to avoid systemic side effects. There are unfortunately many situations where treatment of doubtful efficacy has produced severe side effects. Despite the overall benefit of steroids in ophthalmology, there is a pressing need to find alternative treatment for a variety of blinding disorders.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 792855      PMCID: PMC2496360          DOI: 10.1136/pgmj.52.612.634

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  24 in total

1.  EFFECT OF CORTICOSTEROIDS ON INTRAOCULAR PRESSURE AND FLUID DYNAMICS. I. THE EFFECT OF DEXAMETHASONE IN THE NORMAL EYE.

Authors:  M F ARMALY
Journal:  Arch Ophthalmol       Date:  1963-10

2.  TOPICAL CORTICOSTEROIDS AND HEREDITY IN PRIMARY OPEN-ANGLE GLAUCOMA.

Authors:  B BECKER; K A HAHN
Journal:  Am J Ophthalmol       Date:  1964-04       Impact factor: 5.258

3.  Cortisone glaucoma.

Authors:  H GOLDMANN
Journal:  Arch Ophthalmol       Date:  1962-11

4.  Optic nerve involvement associated with thyroid dysfunction.

Authors:  R M DAY; F D CARROLL
Journal:  Trans Am Ophthalmol Soc       Date:  1961

5.  The unfavorable effect of topical steroid therapy on herpetic keratitis.

Authors:  P THYGESON; M J HOGAN; S J KIMURA
Journal:  Trans Am Ophthalmol Soc       Date:  1960

6.  Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis.

Authors:  R L BLACK; R B OGLESBY; L VON SALLMANN; J J BUNIM
Journal:  JAMA       Date:  1960-09-10       Impact factor: 56.272

7.  Treatment of herpes zoster ophthalmicus with corticotropin and corticosteroids.

Authors:  H G SCHEIE; T G McLELLAN
Journal:  Arch Ophthalmol       Date:  1959-10

8.  Prednisone and prednisolone in ophthalmology; further experimental and clinical observations.

Authors:  J H KING; J W PASSMORE; R A SKEEHAN; J R WEIMER
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1955 Nov-Dec

9.  Intraocular penetration of prednisone and prednisolone.

Authors:  I H LEOPOLD; H S KROMAN; H GREEN
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1955 Nov-Dec

10.  Cataracts in patients with rheumatic diseases treated with corticosteroids. Further observations.

Authors:  R B OGLESBY; R L BLACK; L VON SALLMANN; J J BUNIM
Journal:  Arch Ophthalmol       Date:  1961-11
View more
  4 in total

1.  Tacrolimus Loaded PEG-Cholecalciferol Based Micelles for Treatment of Ocular Inflammation.

Authors:  Shallu Kutlehria; Imran Vhora; Arvind Bagde; Nusrat Chowdhury; Gautam Behl; Ketan Patel; Mandip Singh
Journal:  Pharm Res       Date:  2018-04-16       Impact factor: 4.200

2.  Predisposing factors, microbiological features and outcomes of patients with clinical presumed concomitant microbial and herpes simplex keratitis.

Authors:  Maria Cabrera-Aguas; Pauline Khoo; C R Robert George; Monica M Lahra; Stephanie L Watson
Journal:  Eye (Lond)       Date:  2021-02-19       Impact factor: 3.775

3.  Mesenchymal Stromal Cells Inhibit Neutrophil Effector Functions in a Murine Model of Ocular Inflammation.

Authors:  Sharad K Mittal; Alireza Mashaghi; Afsaneh Amouzegar; Mingshun Li; William Foulsham; Srikant K Sahu; Sunil K Chauhan
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-03-01       Impact factor: 4.799

4.  Tear Fluid Pharmacokinetics Following Oral Prednisone Administration in Dogs With and Without Conjunctivitis.

Authors:  Lionel Sebbag; Yuqi Yan; Joe S Smith; Rachel A Allbaugh; Larry W Wulf; Jonathan P Mochel
Journal:  J Ocul Pharmacol Ther       Date:  2019-05-09       Impact factor: 2.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.